Publications

The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023

Auteurs : Tanya J. Murphy, Hanna Swail, Jaspreet Jain, Maureen Anderson, Philip Awadalla, Lesley Behl, Patrick E. Brown, Carmen L. Charlton, Karen Colwill, Steven J. Drews, Anne-Claude Gingras, Deena Hinshaw, Prabhat Jha, Jamil N. Kanji, Victoria A. Kirsh, Amanda L. S. Lang, Marc-André Langlois, Stephen Lee, Antoine Lewin, Sheila F. O'Brien, Chantale Pambrun, Kimberly Skead, David A. Stephens, Derek R. Stein, Graham Tipples, Paul G. Van Caeseele, Timothy G. Evans, Olivia Oxlade, Bruce D. Mazer, David L. Buckeridge

This study used data from the COVID-19 Immunity Task Force, which includes CanPath data, to track the prevalence of SARS-CoV-2 antibodies in the Canadian population over the pre-vaccination period, the vaccine rollout, and the emergence of the Omicron variant. By March 2023, over three-quarters of the population had detectable antibodies, with the most substantial increases seen after the arrival of the Omicron variant. However, variations in immunity by age and geography highlight the importance of tailoring public health policies and clinical decisions to local patterns of population immunity, considering factors like potential antibody decline and the emergence of new variants that might evade immunity.